MOESM1 of Effects of linagliptin on endothelial function and postprandial lipids in coronary artery disease patients with early diabetes: a randomized, placebo-controlled, double-blind trial
Norbert Tripolt
Felix Aberer
Regina Riedl
Jasmin Url
Gudrun Dimsity
Andreas Meinitzer
Tatjana Stojakovic
Faisal Aziz
Ronald Hรถdl
Gabriele Brachtl
Dirk Strunk
Marianne Brodmann
Franz Hafner
Harald Sourij
10.6084/m9.figshare.6286979.v1
https://springernature.figshare.com/articles/journal_contribution/MOESM1_of_Effects_of_linagliptin_on_endothelial_function_and_postprandial_lipids_in_coronary_artery_disease_patients_with_early_diabetes_a_randomized_placebo-controlled_double-blind_trial/6286979
Additional file 1: Table S1. Change in cell counts from baseline in linagliptin vs. Placebo groups. FMD: flow mediated dilatation; MTT: meal tolerance test; sVCAM-1: soluble vascular cell adhesion molecule-1; sICAM-1: soluble intercellular adhesion molecule-1.
2018-05-17 05:00:00
Linagliptin
Flow mediated dilatation
RCT
DPP-4 inhibitor
Type 2 diabetes
Coronary artery disease
Endothelial function